MannKind Corporation

NASDAQ:MNKD

Biotechnology

Healthcare
$4.07 -0.51%

-$0.02 today

Market cap
$1.31B
Beta
1.11
P/E (TTM)
-50.3
EPS (TTM)
-$0.08
52W Low $2.23High $6.51

Volume 2.12M

Average 5.73M

MNKD Account Payables

Amounts the company owes suppliers for goods and services received.

MannKind CorporationNASDAQ: MNKD

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables rises 220.3% from a year ago

Account payables stood at $16.14M at the end of Q1 FY2026, up 220.3% from a year earlier and up 78.7% from the prior quarter. Over 3 fiscal years it compounded at -6.5% a year.

Context

  • Account payables amounted to 2.2% of total assets at the end of Q1 FY2026, up 0.9 pp from a year earlier.
  • Account payables increased in 1 of the last 3 fiscal years.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +220.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$16.14M+78.7% QoQ
Last fiscal yearDec 2025
$9.03M+33.0% YoY
Year agoMar 2025
$5.04M+220.3% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+220.3%——
1 year+33.0%——
3-year CAGR-6.5%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
9.03M USD
Year-over-year change
+33.0%
4-year CAGR
+6.8%

Account Payables vs competitors

How MNKD compares with its peers on the latest reported figures

  • MNKD's Mar 2026 account payables of $16.14M is the highest of the 6 companies compared; the peer median is $4.4M.
  • Its year-over-year change of +220.3% is the highest of 6, against a peer median of +2.0%.
  • Account payables amounts to 2.2% of total assets for MNKD, versus a peer median of 1.6%.
MNKD Competitors Peer median
Account Payables for MNKD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MNKDMannKind CorporationMar 2026$16.14M +220.3%-6.5%2.2%
XERSXeris Biopharma Holdings, Inc.Mar 2026$11.47M +80.5%-12.6%2.9%
SPRYARS Pharmaceuticals, Inc.Mar 2026$4.71M +14.9%+51.1%1.6%
NRXPNRx Pharmaceuticals, Inc.Mar 2026$4.4M +2.0%+27.2%37.0%
TBPHTheravance Biopharma, Inc.Mar 2026$1.1M -54.3%+18.2%0.2%
ORMPOramed Pharmaceuticals Inc.Mar 2026$481K -5.5%-41.2%0.2%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding MNKD) $4.4M+2.0%+18.2%1.6%

Competitors are the stored peer set for MNKD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents124.18M69.77M238.48M46.34M74.88M
Short-term Investments79.93M101.08M56.62M150.92M96.46M
Net Receivables4.74M16.8M14.9M11.8M38.37M
Inventory7.15M21.77M28.55M27.89M35.31M
Other Current Assets025.48M34.85M31.36M46.55M
Total Current Assets219.49M234.9M373.39M268.31M291.58M
Property, Plant & Equipment (Net)36.61M45.13M84.22M85.37M82.42M
Goodwill02.43M1.93M1.93M67.6M
Intangible Assets01.15M1.07M5.27M5.07M
Long-term Investments56.62M1.96M7.16M5.48M5.01M
Tax Assets00000
Other Non-current Assets8.44M9.72M7.43M27.49M340.5M
Total Non-current Assets101.67M60.39M101.81M125.54M500.6M
Total Assets321.16M295.28M475.2M393.84M792.18M
Account Payables6.96M11.05M9.58M6.79M9.03M
Short-term Debt6.98M9.57M20M049.24M
Tax Payables001.56M49K0
Deferred Revenue827K1.73M9.09M12.41M15.33M
Other Current Liabilities9.53M16.43M30.97M30.37M69.78M
Total Current Liabilities48.35M67.3M104.13M81.84M171.03M
Long-term Debt281.2M273.49M248.7M36.05M320.36M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)24.49M37.68M69.79M51.16M39.98M
Other Non-current Liabilities175.43M162.01M294.82M291.97M208.05M
Total Non-current Liabilities482.16M478.52M617.24M390.82M672.17M
Total Liabilities530.51M545.82M721.37M472.66M843.2M
Common Stock2.52M2.64M2.7M3.03M3.08M
Retained Earnings(3.13B)(3.22B)(3.23B)(3.2B)(3.2B)
Accumulated OCI0001.11M115K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(209.35M)(250.54M)(246.17M)(78.82M)(51.02M)
Total Debt289.22M288.4M272.62M47.7M473.38M
Net Debt165.04M218.63M34.14M1.36M398.5M

MannKind Corporation

NASDAQ:MNKD

Intrinsic Alpha fair value

Locked

Current Price

$4.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.